Beta-catenin Dysregulation in Thyroid Neoplasms: Down-regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2001 Mar 10

PMID 11238046

Citations 87

Authors

G Garcia-Rostan

R L Camp

A Herrero

M L Carcangiu

D L Rimm

G Tallini

Affiliations

Soon will be listed here.

Abstract

beta-catenin has a role in cell adhesion and Wnt signaling. It is mutated or otherwise dysregulated in a variety of human cancers. In this study we assess beta-catenin alteration in 145 thyroid tumors samples from 127 patients. beta-catenin was localized using immunofluorescence and mutational analysis was performed by single-strand conformational polymorphism. Membrane beta-catenin expression was decreased in eight of 12 (66%) adenomas and in all 115 carcinomas (P: < 0.0001). Among carcinomas, reduced membrane beta-catenin was associated with progressive loss of tumor differentiation (P: < 0.0001). CTNNB1 exon 3 mutations and nuclear beta-catenin localization were restricted to poorly differentiated [7 of 28 (25%) and 6 of 28 cases (21.4%), respectively] or undifferentiated carcinomas [19 of 29 (65.5%) and 14 of 29 (48.3%) cases, respectively]. Poorly differentiated tumors always featured mutations involving Ser and Thr residues and were characterized by Thr to Ile amino acid substitutions (P: = 0.0283). The association between CTNNB1 exon 3 mutations and aberrant nuclear immunoreactivity (P: = 0.0020) is consistent with Wnt activation because of stabilizing beta-catenin mutations. Low membrane beta-catenin expression as well as its nuclear localization or CTNNB1 exon 3 mutations are significantly associated with poor prognosis, independent of conventional prognostic indicators for thyroid cancer but not of tumor differentiation. Analysis of beta-catenin dysregulation may be useful to objectively subtype thyroid neoplasms and more accurately predict outcomes.

Citing Articles

Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.

Hartmann H, Loberg M, Xu G, Schwarzkopf A, Chen S, Phifer C Endocrinology. 2025; 166(3).

PMID: 39951495 PMC: 11843548. DOI: 10.1210/endocr/bqaf030.

Exploring the potential of myo-inositol in thyroid disease management: focus on thyroid cancer diagnosis and therapy.

Razavi S, Kalari M, Haghzad T, Haddadi F, Nasiri S, Hedayati M Front Endocrinol (Lausanne). 2024; 15:1418956.

PMID: 39329107 PMC: 11424451. DOI: 10.3389/fendo.2024.1418956.

Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma.

Diaz D, Bergdorf K, Loberg M, Phifer C, Xu G, Sheng Q Endocrine. 2024; 86(1):114-118.

PMID: 38806891 PMC: 11444896. DOI: 10.1007/s12020-024-03887-0.

Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.

Wu M, Yuan H, Zou W, Xu S, Liu S, Gao Q Clin Transl Oncol. 2023; 26(4):808-824.

PMID: 37864677 DOI: 10.1007/s12094-023-03324-0.

β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in -driven thyroid cancer cells.

Zou M, Al-Yahya S, Al-Alwan M, BinEssa H, Khabar K, Almohanna F Front Immunol. 2023; 14:1171816.

PMID: 37483610 PMC: 10358762. DOI: 10.3389/fimmu.2023.1171816.

References

Sparks A, Morin P, Vogelstein B, Kinzler K . Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58(6):1130-4. View

Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T . Suppression of E-cadherin and alpha- and beta-catenin mRNA expression in the metastatic lesions of gynecological cancers. Eur J Gynaecol Oncol. 1997; 18(6):484-7. View

Dierick H, Bejsovec A . Cellular mechanisms of wingless/Wnt signal transduction. Curr Top Dev Biol. 1999; 43:153-90. DOI: 10.1016/s0070-2153(08)60381-6. View

Samowitz W, Powers M, Spirio L, Nollet F, VAN Roy F, Slattery M . Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999; 59(7):1442-4. View

Garcia-Rostan G, Tallini G, Herrero A, DAquila T, Carcangiu M, Rimm D . Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999; 59(8):1811-5. View

Hugh T, Dillon S, Taylor B, Pignatelli M, Poston G, Kinsella A . Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer. 1999; 80(7):1046-51. PMC: 2363041. DOI: 10.1038/sj.bjc.6690461. View

Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S . Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 1999; 23(6):678-85. DOI: 10.1097/00000478-199906000-00007. View

Caca K, Kolligs F, Ji X, Hayes M, Qian J, Yahanda A . Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ. 1999; 10(6):369-76. View

Blaker H, Hofmann W, Rieker R, Penzel R, Graf M, Otto H . Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. 1999; 25(4):399-402. View

10.

Akimoto T, Kawabe S, Grothey A, Milas L . Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clin Exp Metastasis. 1999; 17(2):171-6. DOI: 10.1023/a:1006670918848. View

11.

Lou P, Chen W, Sheen T, Ko J, Hsu M, Wu J . Expression of E-cadherin/catenin complex in nasopharyngeal carcinoma: correlation with clinicopathological parameters. Oncol Rep. 1999; 6(5):1065-71. DOI: 10.3892/or.6.5.1065. View

12.

Wijnhoven B, Pignatelli M . E-cadherin-catenin: more than a "sticky" molecular complex. Lancet. 1999; 354(9176):356-7. DOI: 10.1016/S0140-6736(99)90055-7. View

13.

Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F . Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999; 59(16):3880-2. View

14.

Espada J, Perez-Moreno M, BRAGA V, Rodriguez-Viciana P, Cano A . H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes. J Cell Biol. 1999; 146(5):967-80. PMC: 2169475. DOI: 10.1083/jcb.146.5.967. View

15.

Nhieu J, Renard C, Wei Y, Cherqui D, Zafrani E, Buendia M . Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999; 155(3):703-10. PMC: 1866892. DOI: 10.1016/s0002-9440(10)65168-1. View

16.

Huang S, Wu J, Chang K, Liaw K, Wang S . Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue. Thyroid. 1999; 9(11):1095-103. DOI: 10.1089/thy.1999.9.1095. View

17.

Ramesh S, Nash J, McCulloch P . Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer. 1999; 81(8):1392-7. PMC: 2362972. DOI: 10.1038/sj.bjc.6693437. View

18.

Miller J, Hocking A, Brown J, Moon R . Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 2000; 18(55):7860-72. DOI: 10.1038/sj.onc.1203245. View

19.

Huang H, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, Ohgaki H . APC mutations in sporadic medulloblastomas. Am J Pathol. 2000; 156(2):433-7. PMC: 1850060. DOI: 10.1016/S0002-9440(10)64747-5. View

20.

Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T . Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol. 2000; 156(3):865-70. PMC: 1876834. DOI: 10.1016/s0002-9440(10)64955-3. View